Skip to main content

BNR · Burning Rock Biotech Ltd

Track BNR — free
$13.32 +0.25 (+1.91%) At close · Nov 19
Market Cap
$140.48M
Shares
10.55M
Volume · Nov 19 29.47K Avg daily vol (3M) 35.68K

Price & Indicators

 

Key stats

Close
$13.32
Open
$13.29
Day range
$12.98–14.31
52-week closing range
$7.04–41.06
Average volume, 30 days
24K
Short interest
34K · 0.3% of shares · 1.3 days
Short volume, last session
58%
Last earnings
Mar 29, 2024
Price history
Jun 2020 to Nov 2026

Up next

call held Mar 29, 2024

Latest documents

2026
Nov 17
Current report 6-K
Annual general meeting set for December 22, 2026

Burning Rock Biotech will hold its annual general meeting on December 22, 2026, seeking ratification of Ernst & Young Hua Ming LLP as auditor and re-election of directors Zhihong (Joe) Zhang and Wendy Hayes.

3 source passages
Burning Rock Announces 2026 Annual General Meeting to be Held on December 22, 2026 the appointment of Ernst & Young Hua Ming LLP as auditor of the Zhihong (Joe) Zhang and Wendy Hayes be Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$71.61M
Trailing 12 months
Net income (TTM)
−$9.74M
Trailing 12 months
Revenue growth YoY
-9.3%
Year over year
Operating margin
-13.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$61.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-100.0%
Year over year · fewer shares
Price change (1Y)
-16.9%
Trailing year
Short interest
0.3%
Latest settlement · 1.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −4%
below
RSI (14) 53
neutral
MACD trend Positive
52-week position 18%
mid-range
Momentum
relative strength
Strong
1-month return +1%
trailing
6-month return +43%
trailing
YTD return −34%
this year
Relative strength +49%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $14 › 200d $15 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.33% of shares out · ▼ -6.9% MoM · 1.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Squeeze score 40
low risk · 0–100
Fundamentals
Strong
Revenue growth +9%
Y/Y
Gross margin 75%
expanding
Free cash flow $-4.8M
Buyback $10.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 124%
annualized · 1-yr
Max drawdown −83%
past year
ATR 9.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−4% Neutral
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
18% Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $14 › 200d $15 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.33% of shares out · ▼ -6.9% MoM · 1.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7 Now $13 · 18% Range high $41
vs 200-day avg -11% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BNR
Burning Rock Biotech Ltd
this stock
$140.48M -33.9% +9.2% — 0.3%
TMO
Thermo Fisher Scientific Inc.
$255.19B +18.9% +14.5% 36.3 1.3%
DHR
Danaher Corp
$160.10B -0.6% +8.5% 37.2 1.2%
IDXX
Idexx Laboratories Inc
$54.33B +1.9% +10.4% 46.5 3.0%
A
Agilent Technologies, Inc.
$49.43B +28.9% +6.4% 34.5 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
17
% held
16.1%
Net QoQ
-41.6K sh
Top holder
Kynam Capital Management,…
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
34.3K
Days to cover
1.3d
Change
-2.6K sh
View
Short Volume
Short vol %
58%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
376
Value
$4.2K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
7.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
CNY 539.6M
Net income (FY)
CNY -55.3M
View
Buybacks
Authorized
$10.0M
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 17, 2026
This year
5

Burning Rock Biotech will hold its annual general meeting on December 22, 2026, seeking ratification of Ernst & Young Hua Ming LLP as auditor and re-election of directors Zhihong (Joe) Zhang and Wendy Hayes.

View
Earnings & Events
Webcasts
Last webcast
Mar 29, 2024
View
Investor Relations
Latest news
Burning Rock Presents STELLA Clin…
Published
Oct 27, 2026
View

Performance

5D 20D 120D MTD YTD
BNR -0.1% +0.5% +42.9% +22.2% -33.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +5.4% +6.8% +48.6% +27.5% -38.9%

Capital returns

Buyback program · as of Jun 30, 2022
Authorized
$10.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1792267 CUSIP 12233L206 13F (30d) 19 filings 17 filers Visit website Investor relations